- Quantity label
- 1,000 mg; volume and concentration need confirmation
- Quarterly text
- Save $127.86; billing interpretation unresolved
- Monthly price
- $158.93 advertised
The monthly offer is the clearest published basis
Trava's NAD+ injection page displays $158.93 monthly. The product description identifies NAD+ and shows a 1,000 mg quantity label. These are the public details attached to the injection listing; the exact prescription and dispensing specification still require confirmation through the provider and pharmacy before a reader can determine the supply received.
This review uses the monthly figure rather than importing a lower as-low-as number from another part of the site. A price with cents can look unusually precise while still leaving important conditions unstated. It should be read as an advertised monthly offer, not a guarantee of eligibility, the complete invoice or the clinical result.
Do not infer the quarterly total from Save
The same page displays Save $127.86 with the quarterly-package wording. That presentation does not clearly establish whether $127.86 is an amount saved or a price equivalent. We have not completed checkout, so neither interpretation is converted into a published quarterly bill or a claimed saving over three monthly purchases.
Ask for the amount due now, the period covered, the quantity delivered and the renewal schedule of the quarterly selection. Then compare those answers with the $158.93 monthly option. The full payment and exit conditions matter if the clinical plan changes, especially when a lower equivalent requires a larger initial commitment.
Identify the vial and included care
The 1,000 mg label describes a total amount, not a concentration or individualized administration schedule. Request the vial volume, concentration, dispensing pharmacy and supply instructions. Those details prevent a reader from confusing a package amount with a dose or assuming the same duration as another provider's product carrying a similar headline quantity.
Also establish whether consultation, injection supplies, shipping and follow-up are included, and whether any testing is separately charged. Trava's public product page does not provide enough detail to settle every potential component of care. Unknown costs should remain open questions rather than being silently treated as zero in a budget worksheet.
The evidence question is independent of billing
Trava explains NAD+ in terms of its role in cellular energy production and metabolic processes. Those mechanisms do not prove that the proposed injection produces the advertised wellness effects for an individual. We did not verify a finished-product trial establishing a predictable benefit, nor did we test the provider's clinical or delivery service.
The provider discloses that compounded medications are not FDA-approved. Ask the clinician to explain the intended purpose and relevant evidence, then obtain pharmacy-specific storage and beyond-use guidance. The practical review finding is a monthly injection price that can be documented, alongside a quarterly statement and package details that need clarification. Keep those evidence and commercial questions separate when deciding whether the offer is worth pursuing.
Sources & further reading
Official pages and evidence consulted for this article. Checked October 11, 2026. Provider pages establish advertised terms; they do not independently establish effectiveness.